BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME	POSITION TITLE
Eric C. Petrie, MD	Associate Professor
eRA COMMONS USER NAME EPETRIE	

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
Western Washington University, Bellingham, WA	BA	1978	Physiological Psychology
University of Wisconsin, Madison, WI	MS	1981	Clinical Psychology
Univ. Washington School of Medicine, Seattle, WA	MD	1985	Medicine
Univ. Washington School of Medicine, Seattle, WA	Intern	1986	Medicine
Stanford University, Palo Alto, CA	Resident	1989	Psychiatry
VA Medical Center, Palo Alto, CA	Fellow	1990	Psychiatry

A. Positions and Honors.

Positions and Employment

1990-1994 Acting Instructor, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA
1990-present Staff Psychiatrist, VA Puget Sound Health Care System, Seattle, WA
1994-1996 Chief, Inpatient Section, Psychiatry Service, VA Puget Sound Health Care System, Seattle, WA
1994-2001 Assistant Professor, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA
1996-2001 Medical Director, Evaluation and Brief Treatment Posttraumatic Stress Disorder Unit (EBTPU), VA Puget Sound Health Care System, Seattle, WA
2001-present Associate Professor, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA

Other Experience and Professional Memberships

1990-present Member, American Psychiatric Association
1991-present Member, Society for Biological Psychiatry
1994-present Member, Society for Neuroscience
1995-present Member, American Society of Clinical Psychopharmacology

Honors

1978 Graduated Magma Cum Laude, Western Washington University, Bellingham, WA
1984 Rock Sleyster Scholar, American Medical Association
1999 Young Faculty Development Program, Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA
1999 Chief Resident's Award for Teaching, Psychiatry Residency Training Program, University of Washington, Seattle, WA

B. Selected Peer-Reviewed Publications.

Petrie EC, Tiffany ST, Baker TB, Dahl JL. Dynorphin (1-13): analgesia, hypothermia, cross-tolerance with morphine and beta-endorphin. Peptides 3:41-7, 1982.
Tiffany ST, Petrie EC, Martin EM, and Baker TB. Drug signals enhance morphine tolerance development in hypophysectomized rats. Psychopharmacology 79:84-85, 1983.
Tiffany ST, Petrie EC, Baker TB, Dahl JL. Conditioned morphine tolerance in the rat: absence of a compensatory response and cross-tolerance with stress. Behav Neurosci 97:335-53, 1983.
Petrie EC, Matsumoto AM, and Bremner WJ. Modulation of luteinizing hormone pulse amplitude by the frequency of luteinizing hormone-releasing hormone stimulation and by testosterone in castrated, hypothalamic-lesioned rats. Biology of Reproduction 38:143-149, 1988.

Petrie EC, Faustman WO, Moses JA, Lombrozo L, and Csernansky JG. Correlates of rapid neuroleptic response in male patients with schizophrenia. Psychiatry Research 33:171-177, 1990.
Petrie EC, Lombrozo L, and Csernansky JG. A microassay for measuring synaptosomal 3H-dopamine and 3H-metabolite release. Brain Research Bulletin 25:423-427, 1990.
Szot P, Ashleigh EA, Kohen R, Petrie E, Dorsa DM, and Veith R. Norepinephrine transporter mRNA is elevated in the locus coeruleus following short- and long-term desipramine treatment. Brain Research 618:308-312, 1993.
Petrie EC, Veith RC, and Szot P. Bupropion and desipramine increase dopamine transporter mRNA expression in the ventral tegmental area/substantia nigra of rat brain. Progress in Neuropsychopharmacology and Biological Psychiatry 22:845-856, 1998.
Peskind ER, Elrod R, Dobie DJ, Pascualy M, Petrie E, Jensen C, Brodkin K, Murray S, Veith RC, and Raskind MA. Cerebrospinal fluid epinephrine in Alzheimer's disease and normal aging. Neuropsychopharmacology 19:465-471, 1998.
Petrie EC, Wilkinson CW, Murray S, Jensen C, Peskind ER, and Raskind MA. Effects of Alzheimer's disease and gender on the hypothalamic-pituitary-adrenal axis response to lumbar puncture stress. Psychoneuroendocrinology 24:385-395, 1999.
Pascualy M, Petrie EC, Brodkin K, Peskind ER, and Raskind MA. Effects of advanced aging on plasma catecholamine responses to thermal stress. Neurobiology of Aging 20:637-642, 1999.
Petrie EC, Peskind ER, Dobie DJ, Veith RC, and Raskind MA. Increased plasma norepinephrine response to yohimbine in elderly men. Journal of Gerontology: Medical Sciences 55A:MI55-MI59, 2000.
Raskind MA, Dobie DJ, Kanter E, Petrie EC, and Peskind ER. The alpha-1 adrenergic antagonist prazosin ameliorates combat trauma nightmares in African-American veterans with posttraumatic stress disorder. Journal of Clinical Psychiatry 62:129-133, 2000.
Pascualy M, Petrie EC, Brodkin K, Peskind ER, Wilkinson CW, and Raskind MA. Hypothalamic-pituitary adrenocortical and sympathetic nervous system responses to the cold pressor test in Alzheimer's disease. Biological Psychiatry 48:247-254, 2000.
Petrie EC, Peskind ER, Pascualy M, Dobie DJ, Veith RC, and Raskind MA. Plasma catecholamine and cardiovascular responses to physostigmine in Alzheimer's disease and aging. Psychoneuroendocrinology 26:147-164, 2001.
Wilkinson CW, Petrie EC, Murray SR, Colasurdo EA, Raskind MA, and Peskind ER. Human glucocorticoid feedback inhibition is reduced in older individuals: evening study. Journal of Clinical Endocrinology and Metabolism 86:545-550, 2001.
Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, and Raskind MA. Increased CSF cortisol in Alzheimer's disease is a function of apolipoprotein E genotype. Neurology 56:1094-1098, 2001.
Kanter ED, Wilkinson CW, Radant AD, Petrie EC, Dobie DJ, McFall ME, Peskind ER, and Raskind MA. Glucocorticoid feedback sensitivity and adrenocortical responsiveness in PTSD. Biological Psychiatry 50:238-245, 2001.
Raskind MA, Thompson C, Petrie EC, Dobie DJ, Rein RJ, Hoff DJ, McFall MM, Peskind ER. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. Journal of Clinical Psychiatry 63:565-568, 2002.
Minoshima S, Foster NL, Petrie EC, Albin RL, Frey KA, Kuhl DE. Neuroimaging in dementia with Lewy bodies: Metabolism, Neurochemistry, and Morphology**.** American Journal of Geriatric Psychiatry & Neurology 15:200-209, 2002.
Raskind MA, Peskind ER, Kanter E, Petrie E, Radant A, Thompson C, Dobie DJ, Hoff D, Rein R, Straits-Troster K, Thomas R, McFall MM. Prazosin reduces nightmares and other PTSD symptoms in combat veterans: A placebo-controlled study. American Journal of Psychiatry 160:369-371, 2003.
Li G, Cherrier MM, Tsuang D, Petrie E, Colasurdo E, Craft S, Schellenberg GD, Wilkinson C, Peskind E, Raskind M. Salivary cortisol and memory function in human aging. Neurobiology of Aging 27(11):1705-14, 2006.
Tsuang DW, Riekse RG, Purganan KM, David AC, Montine TJ, Schellenberg GD, Steinbart EJ, Petrie EC, Bird TD, Leverenz JB. Lewy body pathology in late-onset familial Alzheimer's disease: a clinicopathological case series. Journal of Alzheimer’s Disease 9(3):235-42, 2006.
Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard WR, Peskind ER. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. Journal of Alzheimer’s Disease 10(4):399-406, 2006.
Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, Peskind ER, Raskind MA, Breitner JC, Montine TJ. Statin therapy is associated with reduced neuropathologic changes of Alzheimer's disease. Neurology. 69(9):878-85, 2007.

Vuletic S, Li G, Peskind ER, Kennedy H, Marcovina SM, Leverenz JB, Petrie E, Lee VM-Y, Galasko D, Schellenberg GD, Albers JJ. ApoE highly correlates with APP- and tau-related markers in human CSF. Journal of Alzheimer's Disease, in press.

Minoshima S, Sasaki T, Petrie E. FDG PET Imaging of Dementia: Principles and Clinical Applications. In: Wahl RL, Beanlands RSB (Eds.): Principles and Practice of PET and PET/CT, 2nd Edition. Lippincott Williams & Wilkins, Philadelphia, in press.

Pascualy M, Wang L, Petrie EC, Murray S, Peskind ER. Management of Agitation in Dementia. In: Halter JB, Ouslander JG, Tinetti M, Woolard N, Studenski S, Asthana S, High K (Eds.): Hazzard's Geriatric Medicine and Gerontology, 6th Edition. McGraw-Hill, in press.

C. Research Support

Ongoing Research Support

1 KO8 AG23670 (Petrie PI) 8/15/05-3/30/10
NIA
Dopamine and Choline Transporter Imaging in DLB and AD
Role: PI
The major goals of this study are to investigate the involvement of brain alpha-1 noradrenergic receptors (A1AR) in the etiology and pathogenesis of disruptive agitation in Alzheimer's disease and Lewy Body dementia via development and characterization of A1AR SPECT and PET imaging compounds.

Completed Research Support

P50 AG05136
Alzheimer's Disease Research Center
UW ADRC Pilot Grant (Petrie PI) 5/1/03-4/30/04
Imaging of Brain Noradrenergic Activity in Alzheimer's
Role: PI